Research News
View articles by month and year
-
Taxol Plus Tykerb Better Than Taxol Alone to Treat HER2-Positive, Metastatic Disease
The combination of Taxol and Tykerb offers more benefits in treating newly diagnosed metastatic, HER2-positive breast cancer than Taxol alone.
-
Very Early Study Suggests Herceptin May Help Treat Some HER2-Negative Breast Cancers
A very early study done in mice suggests that Herceptin may effectively treat very small breast cancer tumors in bones, even though the original cancer was classified as HER2-negative.
-
T-DM1 (Kadcyla) Wins FDA Approval
Kadcyla, a targeted therapy medicine, has been approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin and a taxane chemotherapy.
-
New Studies Show Avastin Provides Little Benefit for Breast Cancer
More research shows that Avastin offers few benefits in treating breast cancer.
-
Heart Problems Happen More Often Than Thought in Older Women After Herceptin Treatment
A large study has found that older women diagnosed with early-stage, HER2-positive breast cancer treated with Herceptin have a higher risk of heart failure than women who didn’t get Herceptin.
-
T-DM1 Granted Priority Review by FDA
The U.S. Food and Drug Administration has granted priority review to T-DM1 to treat HER2-positive, metastatic breast cancer.
-
Tykerb and Xeloda Seem to Shrink HER2-Positive Breast Cancer That’s Spread to Brain
A very small, very early study suggests the combination of Tykerb and Xeloda shrinks HER2-positive breast cancer lesions in the brain without radiation.
-
One Year of Herceptin Best for Reducing Recurrence Risk of Early-Stage HER2-Positive Disease
Results from two studies confirm that 1 year of Herceptin, rather than 2 years or 6 months, after surgery seems to be best for reducing recurrence risk in women diagnosed with HER2-positive early-stage breast cancer.
-
T-DM1 Lengthens Survival in Women Diagnosed with HER2-Positive Advanced-Stage Disease
Women diagnosed with HER2-positive advanced-stage breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
-
T-DM1 Improves Survival in Women with HER2-Positive Metastatic Breast Cancer
Women diagnosed with HER2-positive metastatic breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
